top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.

Biblioteca

MARC Lista (tabellare)
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Pubbl/distr/stampa London, : Novartis Foundation, 2008
Descrizione fisica 1 online resource (224 p.)
Disciplina 616.46206
Collana Novartis Foundation symposium
Soggetto topico Diabetes - Immunotherapy
Diabetes - Treatment
Soggetto genere / forma Electronic books.
ISBN 1-281-84052-1
9786611840525
0-470-69740-7
0-470-69741-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
Record Nr. UNINA-9910144093303321
London, : Novartis Foundation, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Pubbl/distr/stampa London, : Novartis Foundation, 2008
Descrizione fisica 1 online resource (224 p.)
Disciplina 616.46206
Collana Novartis Foundation symposium
Soggetto topico Diabetes - Immunotherapy
Diabetes - Treatment
ISBN 1-281-84052-1
9786611840525
0-470-69740-7
0-470-69741-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
Record Nr. UNISA-996217070603316
London, : Novartis Foundation, 2008
Materiale a stampa
Lo trovi qui: Univ. di Salerno
Opac: Controlla la disponibilità qui
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]
Pubbl/distr/stampa London, : Novartis Foundation, 2008
Descrizione fisica 1 online resource (224 p.)
Disciplina 616.46206
Collana Novartis Foundation symposium
Soggetto topico Diabetes - Immunotherapy
Diabetes - Treatment
ISBN 1-281-84052-1
9786611840525
0-470-69740-7
0-470-69741-5
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
Record Nr. UNINA-9910830043703321
London, : Novartis Foundation, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Defining optimal immunotherapies for type 1 diabetes / / [editors: Gregory Bock and Jamie Goode]
Defining optimal immunotherapies for type 1 diabetes / / [editors: Gregory Bock and Jamie Goode]
Pubbl/distr/stampa London, : Novartis Foundation, 2008
Descrizione fisica 1 online resource (224 p.)
Disciplina 616.46206
Collana Novartis Foundation symposium
Soggetto topico Diabetes - Immunotherapy
Diabetes - Treatment
ISBN 9786611840525
9781281840523
1281840521
9780470697405
0470697407
9780470697412
0470697415
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
Record Nr. UNINA-9911019280003321
London, : Novartis Foundation, 2008
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui